Initial commit
This commit is contained in:
507
skills/treatment-plans/references/intervention_guidelines.md
Normal file
507
skills/treatment-plans/references/intervention_guidelines.md
Normal file
@@ -0,0 +1,507 @@
|
||||
# Evidence-Based Intervention Guidelines
|
||||
|
||||
## Overview
|
||||
|
||||
This reference provides comprehensive guidance on selecting, implementing, and documenting evidence-based interventions across pharmacological, non-pharmacological, and procedural treatment modalities. These guidelines support treatment plan development with current best practices and clinical recommendations.
|
||||
|
||||
## Evidence Hierarchy
|
||||
|
||||
### Levels of Evidence
|
||||
|
||||
**Level I: Highest Quality**
|
||||
- Systematic reviews and meta-analyses of randomized controlled trials (RCTs)
|
||||
- Large multi-center RCTs
|
||||
|
||||
**Level II: High Quality**
|
||||
- Individual RCTs
|
||||
- Systematic reviews of observational studies
|
||||
|
||||
**Level III: Moderate Quality**
|
||||
- Cohort studies
|
||||
- Case-control studies
|
||||
- Well-designed observational studies
|
||||
|
||||
**Level IV: Lower Quality**
|
||||
- Case series
|
||||
- Case reports
|
||||
- Expert opinion
|
||||
|
||||
**Recommendation Strength**:
|
||||
- **Grade A**: Strong recommendation, high-quality evidence
|
||||
- **Grade B**: Moderate recommendation, moderate-quality evidence
|
||||
- **Grade C**: Weak recommendation, low-quality evidence
|
||||
- **Grade D**: Recommendation against (evidence of harm or no benefit)
|
||||
|
||||
## Pharmacological Interventions
|
||||
|
||||
### Medication Selection Principles
|
||||
|
||||
#### 1. Evidence-Based Prescribing
|
||||
- Use medications with proven efficacy for indication
|
||||
- Follow clinical practice guidelines
|
||||
- Consider comparative effectiveness data
|
||||
- Prefer medications with better safety profiles when equivalent efficacy
|
||||
|
||||
#### 2. Patient-Specific Factors
|
||||
- Comorbidities and contraindications
|
||||
- Organ function (renal, hepatic)
|
||||
- Drug allergies and intolerances
|
||||
- Concurrent medications (drug interactions)
|
||||
- Age, pregnancy status
|
||||
- Genetic factors (pharmacogenomics when available)
|
||||
- Cost and insurance coverage
|
||||
|
||||
#### 3. Medication Safety
|
||||
- Start low, go slow (especially in elderly, multiple comorbidities)
|
||||
- Titrate to target dose based on response and tolerance
|
||||
- Monitor for adverse effects
|
||||
- Avoid potentially inappropriate medications (Beers Criteria for elderly)
|
||||
- Polypharmacy reduction when possible
|
||||
|
||||
### Common Medication Classes by Indication
|
||||
|
||||
#### Hypertension
|
||||
|
||||
**First-Line Agents** (per JNC-8, ACC/AHA guidelines):
|
||||
- **ACE Inhibitors** (lisinopril, enalapril): Preferred if diabetes, CKD, or heart failure
|
||||
- **ARBs** (losartan, valsartan): Alternative to ACE if intolerant
|
||||
- **Calcium Channel Blockers** (amlodipine): Particularly effective in elderly, Black patients
|
||||
- **Thiazide Diuretics** (chlorthalidone, HCTZ): Cost-effective, good CV outcomes
|
||||
|
||||
**Dosing Strategy**:
|
||||
- Start single agent at low dose
|
||||
- Titrate to maximum tolerated dose before adding second agent
|
||||
- Combination therapy often needed (2-3 agents)
|
||||
- Monitor BP response, adjust every 2-4 weeks
|
||||
|
||||
#### Type 2 Diabetes Mellitus
|
||||
|
||||
**First-Line** (ADA Standards of Care):
|
||||
- **Metformin**: First-line for all patients unless contraindicated (eGFR <30)
|
||||
- Start 500-850mg daily or BID, titrate to 2000mg total daily
|
||||
|
||||
**Second-Line** (individualize based on comorbidities):
|
||||
- **SGLT2 Inhibitors** (empagliflozin, dapagliflozin): If heart failure or CKD (strong cardio-renal benefits)
|
||||
- **GLP-1 Receptor Agonists** (semaglutide, dulaglutide): If ASCVD or high risk, weight loss needed
|
||||
- **DPP-4 Inhibitors** (sitagliptin): If low hypoglycemia risk desired
|
||||
- **Sulfonylureas** (glipizide): Cost-effective but hypoglycemia risk
|
||||
- **Insulin**: If HbA1c very elevated ($>$10%) or symptoms of hyperglycemia
|
||||
|
||||
#### Depression
|
||||
|
||||
**First-Line SSRIs** (APA guidelines):
|
||||
- Sertraline, escitalopram, fluoxetine, citalopram, paroxetine
|
||||
- Start low (e.g., sertraline 50mg, escitalopram 10mg)
|
||||
- Titrate after 2-4 weeks if partial response
|
||||
- Full trial: 6-8 weeks at therapeutic dose
|
||||
- Continue 6-12 months after remission (longer if recurrent)
|
||||
|
||||
**Second-Line**:
|
||||
- **SNRIs** (venlafaxine, duloxetine): Especially if chronic pain comorbidity
|
||||
- **Bupropion**: If sexual dysfunction concern, smoking cessation
|
||||
- **Mirtazapine**: If insomnia/appetite stimulation needed
|
||||
|
||||
**Augmentation** (if partial response):
|
||||
- Second antidepressant from different class
|
||||
- Atypical antipsychotic (aripiprazole, quetiapine) - FDA-approved augmentation
|
||||
- Lithium, thyroid hormone (triiodothyronine)
|
||||
|
||||
#### Chronic Pain
|
||||
|
||||
**Multimodal Analgesia** (WHO Pain Ladder, CDC Opioid Guidelines):
|
||||
|
||||
**Non-Opioid Analgesics**:
|
||||
- **Acetaminophen**: 3-4g/day divided, safe if liver function normal
|
||||
- **NSAIDs**: Ibuprofen, naproxen, meloxicam - short-term or chronic with GI protection
|
||||
- Monitor: Renal function, BP, GI bleeding risk
|
||||
|
||||
**Adjuvant Analgesics for Neuropathic Pain**:
|
||||
- **Gabapentin**: 300mg titrated to 1800-3600mg/day divided TID
|
||||
- **Pregabalin**: 75mg BID titrated to 150-300mg BID (better bioavailability than gabapentin)
|
||||
- **SNRIs** (duloxetine): 60mg daily for diabetic neuropathy, chronic MSK pain
|
||||
- **TCAs** (amitriptyline, nortriptyline): Low-dose (10-75mg QHS) - second-line due to side effects
|
||||
|
||||
**Topical Agents**:
|
||||
- Lidocaine patches 5%, diclofenac gel, capsaicin cream
|
||||
- Local effect, minimal systemic absorption
|
||||
|
||||
**Opioids** (CDC guidelines - use cautiously):
|
||||
- Only after non-opioid multimodal therapies inadequate
|
||||
- Lowest effective dose, short-acting preferred initially
|
||||
- Avoid $>$90 MME/day if possible
|
||||
- UDS, PDMP monitoring, naloxone co-prescription
|
||||
- Reassess frequently, taper if not meeting functional goals
|
||||
|
||||
#### Heart Failure with Reduced Ejection Fraction (HFrEF)
|
||||
|
||||
**Guideline-Directed Medical Therapy (GDMT)** - "Foundational Four":
|
||||
|
||||
1. **ACE Inhibitor or ARB or ARNI**
|
||||
- ACE: Lisinopril 20-40mg daily, enalapril 10-20mg BID
|
||||
- ARNI (Sacubitril/Valsartan): 24/26mg BID → 97/103mg BID (superior to ACE/ARB)
|
||||
- Monitor: BP, renal function, potassium
|
||||
|
||||
2. **Beta-Blocker**
|
||||
- Carvedilol 3.125-6.25mg BID → 25mg BID (target)
|
||||
- Metoprolol succinate 12.5-25mg daily → 200mg daily
|
||||
- Bisoprolol 1.25mg → 10mg daily
|
||||
- Titrate slowly, monitor HR, BP
|
||||
|
||||
3. **Mineralocorticoid Receptor Antagonist (MRA)**
|
||||
- Spironolactone 12.5-25mg daily (up to 50mg)
|
||||
- Eplerenone 25mg daily → 50mg daily
|
||||
- Monitor: Potassium, renal function (risk hyperkalemia)
|
||||
|
||||
4. **SGLT2 Inhibitor**
|
||||
- Dapagliflozin 10mg daily or empagliflozin 10mg daily
|
||||
- Reduces HF hospitalizations and mortality
|
||||
- Also beneficial for diabetes and CKD
|
||||
|
||||
**Additional Therapies**:
|
||||
- Loop diuretic (furosemide) for volume management (not mortality benefit)
|
||||
- Hydralazine-isosorbide dinitrate (if African American or intolerant to ACE/ARB)
|
||||
- Ivabradine (if EF $\leq$35%, HR $>$70 on max beta-blocker)
|
||||
- Digoxin (symptomatic benefit, reduce hospitalizations)
|
||||
|
||||
### Medication Documentation Best Practices
|
||||
|
||||
**Include in Treatment Plan**:
|
||||
- Generic name (brand name optional)
|
||||
- Dose, route, frequency
|
||||
- Indication/rationale
|
||||
- Titration plan if applicable
|
||||
- Expected timeline for benefit
|
||||
- Key side effects to monitor
|
||||
- Drug interactions
|
||||
- When to adjust or discontinue
|
||||
|
||||
**Example**: "Lisinopril 10mg PO daily - ACE inhibitor for hypertension and renal protection in diabetes. Titrate to 20mg in 2-4 weeks if BP not at goal and tolerating (monitor for cough, hyperkalemia). Target BP <130/80."
|
||||
|
||||
## Non-Pharmacological Interventions
|
||||
|
||||
### Lifestyle Modifications
|
||||
|
||||
#### Diet and Nutrition
|
||||
|
||||
**Mediterranean Diet** (Evidence: multiple RCTs, PREDIMED trial):
|
||||
- **Indications**: Cardiovascular disease prevention, diabetes management
|
||||
- **Components**:
|
||||
- High intake: Fruits, vegetables, whole grains, legumes, nuts, olive oil
|
||||
- Moderate: Fish, poultry
|
||||
- Low: Red meat, sweets
|
||||
- **Evidence**: Reduces cardiovascular events by 30%, improves glucose control
|
||||
- **Implementation**: Dietitian referral for medical nutrition therapy
|
||||
|
||||
**DASH Diet** (Dietary Approaches to Stop Hypertension):
|
||||
- **Indication**: Hypertension
|
||||
- **Components**: High fruits/vegetables, low-fat dairy, reduced sodium (<2300mg, ideally <1500mg)
|
||||
- **Evidence**: Reduces SBP by 8-14 mmHg
|
||||
- **Implementation**: DASH eating plan education, sodium tracking
|
||||
|
||||
**Carbohydrate Counting** (for Diabetes):
|
||||
- Consistent carbohydrate intake: 45-60g per meal
|
||||
- Enables insulin dosing adjustment
|
||||
- Prevents glycemic variability
|
||||
- Dietitian teaches carb counting skills
|
||||
|
||||
**Weight Management**:
|
||||
- Caloric deficit: 500-750 kcal/day for 1-2 lb/week weight loss
|
||||
- Behavior change strategies: Self-monitoring, stimulus control, goal-setting
|
||||
- Structured programs (Weight Watchers, MOVE!, etc.) more effective than self-directed
|
||||
- Pharmacotherapy (GLP-1 agonists, orlistat) or bariatric surgery for BMI $\geq$30-35 with comorbidities
|
||||
|
||||
#### Physical Activity and Exercise
|
||||
|
||||
**Aerobic Exercise**:
|
||||
- **Recommendation**: 150 min/week moderate intensity OR 75 min/week vigorous
|
||||
- **Moderate**: Brisk walking, cycling, swimming - can talk but not sing
|
||||
- **Vigorous**: Running, fast cycling - can say few words before pause
|
||||
- **Benefits**: Cardiovascular health, glucose control, weight management, mood
|
||||
- **Implementation**: Start with 10 min sessions, gradually increase
|
||||
|
||||
**Resistance Training**:
|
||||
- **Recommendation**: 2-3 sessions/week, all major muscle groups
|
||||
- **Benefits**: Muscle strength, bone density, metabolic rate, glucose control
|
||||
- **Implementation**: Bodyweight exercises, resistance bands, free weights, machines
|
||||
|
||||
**Balance and Flexibility**:
|
||||
- Important for fall prevention in elderly
|
||||
- Yoga, tai chi
|
||||
- Stretching routines
|
||||
|
||||
**Exercise Prescription**:
|
||||
- FITT principle: **F**requency, **I**ntensity, **T**ime, **T**ype
|
||||
- Individualize based on fitness level, comorbidities, goals
|
||||
- Cardiac clearance if indicated (using ACSM or ACC/AHA guidelines)
|
||||
|
||||
**Example**: "Aerobic exercise: Walk 30 minutes, 5 days/week at moderate intensity (target HR 50-70% max). Resistance training: Upper and lower body exercises 2x/week, 2 sets of 10-12 reps."
|
||||
|
||||
#### Smoking Cessation
|
||||
|
||||
**Evidence**: Strongest intervention for COPD, cardiovascular disease, cancer prevention
|
||||
|
||||
**5 A's Approach**:
|
||||
1. **Ask**: Screen all patients for tobacco use
|
||||
2. **Advise**: Urge all tobacco users to quit
|
||||
3. **Assess**: Willingness to make quit attempt
|
||||
4. **Assist**: Aid in quitting (counseling + medication)
|
||||
5. **Arrange**: Follow-up contact
|
||||
|
||||
**Pharmacotherapy** (doubles quit rates):
|
||||
- **Nicotine Replacement**: Patch, gum, lozenge - OTC, safe
|
||||
- **Varenicline**: Most effective (Chantix), start 1 week before quit date
|
||||
- **Bupropion**: Alternative, also treats depression
|
||||
- **Combination**: NRT + varenicline/bupropion more effective
|
||||
|
||||
**Counseling**:
|
||||
- Quitline: 1-800-QUIT-NOW
|
||||
- Individual or group counseling
|
||||
- Cognitive-behavioral techniques
|
||||
|
||||
**Implementation**: Set quit date within 30 days, prescribe pharmacotherapy + counseling referral, follow up within 1 week of quit date.
|
||||
|
||||
#### Sleep Hygiene
|
||||
|
||||
**Indications**: Insomnia, poor sleep quality
|
||||
|
||||
**Components**:
|
||||
- Consistent sleep-wake schedule (same bedtime/wake time)
|
||||
- Bedroom: Dark, quiet, cool (60-67°F)
|
||||
- Avoid: Caffeine after 2 PM, alcohol, large meals before bed
|
||||
- Screen time: Stop 1 hour before bed
|
||||
- Wind-down routine: Reading, bath, relaxation
|
||||
- Use bed only for sleep (not TV, work)
|
||||
- If can't sleep after 20 min, get up and do quiet activity
|
||||
|
||||
**Evidence**: Effective for chronic insomnia, often combined with CBT for insomnia (CBT-I)
|
||||
|
||||
#### Stress Management
|
||||
|
||||
**Techniques**:
|
||||
- **Mindfulness meditation**: 10-20 min daily, reduces anxiety, depression
|
||||
- **Progressive muscle relaxation**: Systematic tensing and relaxing muscle groups
|
||||
- **Deep breathing**: Diaphragmatic breathing, 4-7-8 technique
|
||||
- **Yoga, tai chi**: Mind-body practices
|
||||
- **Cognitive restructuring**: Challenge stress-inducing thoughts
|
||||
|
||||
**Evidence**: Reduces stress hormones, improves mood, pain perception
|
||||
|
||||
### Behavioral Interventions
|
||||
|
||||
#### Cognitive Behavioral Therapy (CBT)
|
||||
|
||||
**Indications**: Depression, anxiety, insomnia, chronic pain, substance use
|
||||
|
||||
**Core Components**:
|
||||
- Psychoeducation
|
||||
- Cognitive restructuring (identify and challenge distorted thoughts)
|
||||
- Behavioral activation (increase rewarding activities)
|
||||
- Problem-solving skills
|
||||
- Relapse prevention
|
||||
|
||||
**Evidence**: Equivalent to antidepressants for mild-moderate depression, first-line for anxiety, insomnia
|
||||
|
||||
**Implementation**: 12-16 weekly 50-min sessions with trained therapist, homework between sessions
|
||||
|
||||
**Variants**:
|
||||
- **CBT-I** (insomnia): Sleep restriction, stimulus control, cognitive therapy for sleep
|
||||
- **CBT-CP** (chronic pain): Pain education, activity pacing, cognitive restructuring of pain catastrophizing
|
||||
|
||||
#### Motivational Interviewing (MI)
|
||||
|
||||
**Indication**: Ambivalence about behavior change (diet, exercise, substance use, medication adherence)
|
||||
|
||||
**Principles**:
|
||||
- Express empathy
|
||||
- Develop discrepancy (between current behavior and goals/values)
|
||||
- Roll with resistance (don't argue)
|
||||
- Support self-efficacy
|
||||
|
||||
**Techniques**:
|
||||
- Open-ended questions
|
||||
- Affirmations
|
||||
- Reflective listening
|
||||
- Summarizing
|
||||
- Elicit "change talk"
|
||||
|
||||
**Evidence**: Effective for initiating behavior change in multiple domains
|
||||
|
||||
### Patient Education and Self-Management
|
||||
|
||||
**Components**:
|
||||
- Disease education (pathophysiology, natural history, treatment)
|
||||
- Self-monitoring skills (blood glucose, BP, weight, symptoms)
|
||||
- Medication management (purpose, dosing, side effects)
|
||||
- Symptom recognition and action plans
|
||||
- Lifestyle modification skills
|
||||
- Problem-solving
|
||||
- When to seek care
|
||||
|
||||
**Evidence**: Self-management education improves outcomes in diabetes, asthma, heart failure, chronic pain
|
||||
|
||||
**Delivery**:
|
||||
- Individual education by clinician or educator
|
||||
- Structured programs (DSMES for diabetes, cardiac rehab for heart disease)
|
||||
- Group classes
|
||||
- Written materials, videos, apps
|
||||
|
||||
## Procedural and Interventional Therapies
|
||||
|
||||
### Rehabilitation Therapies
|
||||
|
||||
#### Physical Therapy
|
||||
|
||||
**Indications**: Musculoskeletal injuries, post-surgical rehabilitation, balance/gait disorders, chronic pain
|
||||
|
||||
**Interventions**:
|
||||
- Therapeutic exercise: Strengthening, stretching, endurance
|
||||
- Manual therapy: Soft tissue mobilization, joint mobilization
|
||||
- Gait and balance training
|
||||
- Modalities: Heat, ice, ultrasound, electrical stimulation, TENS
|
||||
- Functional training: ADL retraining, body mechanics
|
||||
|
||||
**Evidence**: Strong evidence for specific conditions (e.g., PT for knee OA reduces pain and improves function equivalent to NSAIDs)
|
||||
|
||||
**Prescription**: Frequency (e.g., 2-3x/week), duration (e.g., 4-8 weeks), specific interventions/goals
|
||||
|
||||
#### Occupational Therapy
|
||||
|
||||
**Indications**: ADL limitations, upper extremity dysfunction, cognitive-perceptual deficits, work-related injuries
|
||||
|
||||
**Interventions**:
|
||||
- ADL/IADL training
|
||||
- Adaptive equipment and environmental modifications
|
||||
- Upper extremity strengthening and coordination
|
||||
- Energy conservation techniques
|
||||
- Cognitive rehabilitation
|
||||
- Work hardening/conditioning
|
||||
|
||||
**Evidence**: Improves independence post-stroke, post-injury, with chronic conditions
|
||||
|
||||
#### Speech-Language Pathology
|
||||
|
||||
**Indications**: Dysphagia, aphasia, dysarthria, cognitive-communication disorders
|
||||
|
||||
**Interventions**:
|
||||
- Swallow therapy and diet modifications
|
||||
- Language therapy (aphasia)
|
||||
- Articulation therapy
|
||||
- Cognitive-linguistic therapy
|
||||
- Augmentative and alternative communication (AAC)
|
||||
|
||||
### Interventional Pain Procedures
|
||||
|
||||
#### Epidural Steroid Injections (ESI)
|
||||
|
||||
**Indication**: Radicular pain from disc herniation or spinal stenosis
|
||||
|
||||
**Evidence**: Moderate-quality evidence for short-term pain relief (3-6 weeks to 3 months), variable long-term benefit
|
||||
|
||||
**Approach**: Fluoroscopy-guided, transforaminal, interlaminar, or caudal
|
||||
|
||||
**Frequency**: Up to 3-4 injections per year
|
||||
|
||||
**Risks**: Infection, bleeding, nerve injury (rare), dural puncture
|
||||
|
||||
#### Radiofrequency Ablation (RFA)
|
||||
|
||||
**Indication**: Facet joint-mediated pain (after positive diagnostic medial branch blocks)
|
||||
|
||||
**Evidence**: Good evidence for lumbar facet pain relief for 6-12 months
|
||||
|
||||
**Procedure**: Thermal lesioning of medial branch nerves supplying facet joints
|
||||
|
||||
**Repeatable**: Can repeat when pain returns
|
||||
|
||||
#### Spinal Cord Stimulation (SCS)
|
||||
|
||||
**Indication**: Refractory chronic neuropathic pain (failed back surgery syndrome, CRPS, diabetic neuropathy)
|
||||
|
||||
**Evidence**: 50-60% achieve $\geq$50% pain relief, improves function
|
||||
|
||||
**Procedure**: Trial lead placement (5-7 days), if successful → permanent implant
|
||||
|
||||
**Technologies**: Traditional, high-frequency, burst stimulation, dorsal root ganglion (DRG)
|
||||
|
||||
### Surgical Interventions
|
||||
|
||||
**When to Refer for Surgery**:
|
||||
- Failed conservative management (adequate trial - typically 6-12 weeks minimum)
|
||||
- Progressive neurologic deficit
|
||||
- Cauda equina syndrome (emergency)
|
||||
- Severe functional limitation affecting quality of life
|
||||
- Structural pathology amenable to surgical correction
|
||||
- Patient preference after risks/benefits discussion
|
||||
|
||||
**Shared Decision-Making**: Discuss operative vs. non-operative management, risks, benefits, expected outcomes, recovery
|
||||
|
||||
## Integrative and Complementary Therapies
|
||||
|
||||
### Acupuncture
|
||||
|
||||
**Evidence**:
|
||||
- **Moderate evidence** for chronic low back pain, osteoarthritis knee pain, tension headaches, migraine
|
||||
- **Mechanism**: Unclear (endorphin release, gate control theory, placebo)
|
||||
|
||||
**Implementation**: 8-12 sessions by licensed acupuncturist
|
||||
|
||||
### Massage Therapy
|
||||
|
||||
**Evidence**: Modest benefit for chronic low back pain, anxiety, cancer-related symptoms
|
||||
|
||||
**Types**: Swedish, deep tissue, myofascial release
|
||||
|
||||
**Implementation**: 1-2x/week, 30-60 min sessions
|
||||
|
||||
### Yoga
|
||||
|
||||
**Evidence**: Improves back pain, balance, flexibility, reduces stress and anxiety
|
||||
|
||||
**Types**: Hatha (gentle), Vinyasa (flowing), Iyengar (alignment-focused)
|
||||
|
||||
**Implementation**: Group classes or home practice, 2-3x/week
|
||||
|
||||
### Mindfulness-Based Stress Reduction (MBSR)
|
||||
|
||||
**Evidence**: Reduces stress, anxiety, depression, chronic pain
|
||||
|
||||
**Program**: 8-week structured program, weekly 2.5-hour sessions, daily home practice
|
||||
|
||||
**Components**: Meditation, body scan, mindful movement (yoga)
|
||||
|
||||
### Chiropractic Care
|
||||
|
||||
**Evidence**: Effective for acute and chronic low back pain, neck pain
|
||||
|
||||
**Techniques**: Spinal manipulation, mobilization, soft tissue therapy
|
||||
|
||||
**Safety**: Generally safe, avoid high-velocity manipulation if osteoporosis, spinal instability
|
||||
|
||||
## Intervention Selection and Documentation
|
||||
|
||||
### Treatment Algorithm Approach
|
||||
|
||||
1. **Diagnosis-Specific**: Follow evidence-based guidelines for condition
|
||||
2. **Severity-Appropriate**: Mild → conservative; severe → aggressive
|
||||
3. **Stepwise Intensification**: Start with first-line, add or switch if inadequate response
|
||||
4. **Multimodal**: Combine complementary interventions (pharmacologic + non-pharmacologic)
|
||||
5. **Individualized**: Adjust for patient factors (comorbidities, preferences, resources)
|
||||
|
||||
### Documentation Template
|
||||
|
||||
For each intervention, document:
|
||||
- **Intervention**: Specific name/type
|
||||
- **Indication**: Why this intervention for this patient
|
||||
- **Evidence**: Guideline-based, RCT data supporting use
|
||||
- **Dose/Frequency/Duration**: Specific parameters
|
||||
- **Expected Benefit**: What should improve, by how much, when
|
||||
- **Monitoring**: How will response be assessed
|
||||
- **Risks/Side Effects**: Key concerns to monitor
|
||||
- **Alternatives Considered**: What else was considered, why not chosen
|
||||
|
||||
---
|
||||
|
||||
**Document Version**: 1.0
|
||||
**Last Updated**: January 2025
|
||||
**Next Review**: January 2026
|
||||
|
||||
Reference in New Issue
Block a user